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Abstract 
Rapid molecular technology can detect the mecA resistance gene in 
Staphylococcus aureus (SA), predicting methicillin susceptibility in under one hour. In 
combination with antimicrobial stewardship program interventions in adults with SA 
bacteremia, rapid mecA testing decreases time to targeted therapy. This intervention has 
not yet been shown effective in pediatric patients or in the absence of real-time 
stewardship interventions. The objective of this study was to determine if time to optimal 
therapy decreased following implementation of GeneXpert rapid diagnostic testing 
(RDT) in a pediatric institution without a formal antimicrobial stewardship protocol for 
response. The primary outcome was time to optimal therapy, determined by the number 
of hours from collection of the blood sample to the initiation of an optimal regimen. 
Optimal regimens were defined as vancomycin therapy alone for MRSA and nafcillin, 
oxacillin, or cefazolin alone for MSSA. 
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Background 
Vancomycin is usually included in empiric antimicrobial regimens to account for 
potential resistance when Staphylococcus aureus (SA) bacteremia is suspected. Once 
organism identification and susceptibility are known, therapy can be optimized to target 
the isolated bacteria, including discontinuation of vancomycin when methicillin-
susceptible Staphylococcus aureus (MSSA) is present. Prolonged vancomycin exposure 
is associated with the risk of renal dysfunction and the development of resistance. The 
widespread use of vancomycin to treat methicillin-resistant Staphylococcus aureus 
(MRSA) has coincided with an increased incidence of vancomycin-resistant enterococci 
infections.1-4 Additionally, vancomycin treatment failure has been associated with the 
increased incidence of heterogenous vancomycin-intermediate SA.5 Minimal use of 
unnecessary vancomycin is advised to prevent the emergence of resistance.6-7 
Beyond the risks associated with vancomycin therapy, optimizing directed 
therapy for MSSA bacteremia may be associated with improved outcomes. Vancomycin 
monotherapy may be inferior to a beta-lactam antibiotic alone or in combination with 
vancomycin in the empiric treatment of MSSA bacteremia, resulting in delayed culture 
clearance, relapse, or infection-related mortality.8-11 Patients initiated on vancomycin and 
switched to nafcillin or cefazolin for completion of therapy were 69% less likely than 
patients continued on vancomycin alone to die from the MSSA infection.12  
The GeneXpert MRSA/SA BC (Cepheid, Sunnyvale, CA) is a rapid diagnostic 
test (RDT) which uses polymerase chain reaction (PCR) assaying technology to detect 
the presence of the Staphylococcus aureus mecA gene in positive blood cultures. The 
mecA gene codes for methicillin resistance via mutation of a penicillin binding protein 
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which has decreased binding affinity to beta-lactam antibiotics. The result is 
differentiation between MSSA and MRSA in blood culture specimens in less than one 
hour as opposed to traditional methods which may take an additional 18 to 48 hours.13 
Prior to GeneXpert implementation, the identification of staphylococcal isolates from 
blood cultures was based solely on phenotypic analysis (VITEK 2; bioMérieux) or 
proteomic profiling (Bruker MALDI biotyper; Bruker) of colonies grown in subculture of 
the positive broths. Phenotypic testing by either VITEK 2 or Etest (bioMérieux) was used 
to determine the antimicrobial susceptibility profiles of isolates in both time periods. In 
combination with antimicrobial stewardship program interventions in adult patients with 
SA bacteremia, rapid PCR testing decreases total hospital costs, pharmacy specific costs, 
and time to infectious disease provider consult.14  
Time to targeted therapy decreases when providers are notified of the RDT result 
as compared to reporting the final result after traditional identification many hours later.15 
Prompt notification to providers with RDT results has been successful through the use of 
a stewardship protocol. In these protocols, antibiotic stewardship practitioners evaluate 
the result, notify providers, and make recommendations for adjusting antimicrobial 
therapy as indicated.14-17 Other studies have shown that without the implementation of a 
stewardship protocol for response, the benefits of RDT are not fully appreciated.18-19 
Although most published data regarding rapid PCR diagnostic testing are in adults, 
studies in the pediatric setting with real-time antimicrobial stewardship support have 
shown decreased time to optimal therapy. However, it is unknown if using GeneXpert in 
a pediatric institution in the absence of a formalized antimicrobial stewardship protocol to 
address the test results provides clinical benefit. Furthermore, few published data 
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describe the impact of PCR technology in children with SA bacteremia. The objective of 
this study was to determine the impact of GeneXpert technology on time to optimal 
therapy in pediatric patients with SA bacteremia at a single tertiary care pediatric 
institution without a formal antimicrobial stewardship intervention. We sought to test the 
hypothesis that GeneXpert testing in this population would be associated with decreased 
vancomycin usage.  
Methods 
This was a retrospective cohort study at a freestanding, 300-bed children’s 
hospital.  GeneXpert technology was implemented at the institution in January 2016. 
GeneXpert testing was utilized for blood cultures after Gram-positive cocci were 
observed in a smear of the culture broth and SA had been identified via rapid peptide 
nucleic acid fluorescence in situ hybridization (PNA-FISH). All laboratory services were 
performed in real-time. A medical laboratory scientist reported the PNA-FISH result to 
the medical team or nurse prior to detection of the mecA gene. If the isolate was SA, the 
results for the mecA testing were provided in the EMR upon completion of the 
GeneXpert test. Once the organism was isolated on solid media, definitive identification 
and antimicrobial susceptibility testing were performed per routine and reported in the 
medical record.   
The institution had a formalized antimicrobial stewardship program during the 
studied time period, but lacked a specific protocol addressing dissemination of the 
GeneXpert result.  Clinical pharmacists were responsible for antimicrobial stewardship 
on each medical service but there was no standardization; i.e. each pharmacist practiced 
their own individual approach. 
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Study Design and Population 
 The study included all patients with positive SA blood cultures at our institution 
during the study time period. Patients in the conventional group (pre-intervention group) 
had a positive blood culture from February 1, 2014 through March 31, 2015, and these 
blood cultures did not undergo GeneXpert testing.  Patients in the GeneXpert group 
(post-implementation group) had a positive blood culture between February 1, 2016 and 
March 31, 2017, after GeneXpert technology was implemented for regular use. Only the 
first positive SA blood culture per study period per patient was included. Patients were 
excluded if they died before any culture results were available, if normal laboratory 
procedure for the specific time frame was not followed, or if result timing was not 
documented clearly in the electronic medical record (EMR). Patients were also excluded 
if no therapy was administered and/or the isolate was considered a contaminant, as 
documented in the EMR.  
 Optimal antimicrobial regimens were defined as vancomycin monotherapy for 
MRSA bacteremia and nafcillin, oxacillin, or cefazolin monotherapy for MSSA 
bacteremia. In patients where rifampin or clindamycin was added to the therapy listed 
above for synergistic purposes, therapy was still considered to be optimal for the 
purposes of this analysis. In patients with an absolute neutrophil count less than 500 
cells/mm3 during therapy, an anti-pseudomonal beta-lactam (piperacillin/tazobactam, 
cefepime, or meropenem) was considered optimal therapy for MSSA due to desired anti-
pseudomonal activity in patients with febrile neutropenia. Adequate therapy was defined 
as any monotherapy or combination therapy where the specifically isolated organism was 
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within the spectrum of activity of the regimen, even if it was not the most narrow 
spectrum treatment.  
 Data including age, sex, hospital service, intensive care unit admission, antibiotic 
allergies, length of hospital stay, time to adequate and optimal therapy, and result of 
susceptibility testing were extracted from the medical record. Specific antimicrobial 
variables such as dose, frequency and duration were also collected.  
 The primary outcome was time to optimal therapy which was defined as the 
number of hours from collection of the blood samples to the initiation of an optimal 
regimen.  Patient data were excluded from the primary outcome analysis if the blood 
culture exhibited polymicrobial growth (more than one pathogen grew from the same 
blood culture), or there was a secondary, concomitant infection with a non-SA pathogen 
at the time of culture collection. Vancomycin usage was assessed specifically in patients 
with monomicrobial MSSA bacteremia. Additional outcomes included time to adequate 
therapy, accuracy of GeneXpert output as compared to traditional bacterial identification 
determined based on matching result (methicillin susceptible or methicillin resistant), and 
length of hospital stay. The secondary outcome of length of stay was compared for the 
whole cohort, including patients with a polymicrobial blood culture. Vancomycin 
utilization was evaluated in patients with monomicrobial MSSA infections exclusively.  
Statistical Analysis 
Continuous data were described using mean and standard deviation (SD) for 
variables considered to be normally distributed and median and interquartile range (IQR) 
for non-normally distributed variables. Categorical variables were compared between 
groups using the Chi-square test or Fisher exact test. Continuous variables were 
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compared using the independent samples t-test or Mann-Whitney U test for non-
parametric data. A p-value of 0.05 was considered to be statistically significant. 
Statistical analyses were conducted using Statistical Package for Social Sciences version 
23.0 (SPSS v23.0).  The study was approved by the institutional review board of the 
hospital. 
Results 
 Overall, 110 patients had a positive SA blood culture during the study period and 
101 patients were included (Figure 1). There were 61 patients in the conventional testing 
group, and 40 patients in the GeneXpert group. 
There were no significant differences in gender, age, or weight between the 
conventional and GeneXpert cohorts (Table 1). In all GeneXpert group cases, the 
presence of the mecA gene, as determined by the RDT, was consistent with the 
identification and susceptibilities reported after completing conventional susceptibility 
testing.  
The primary outcome was analyzed in 50 and 32 patients in the conventional 
testing and GeneXpert groups, respectively, after excluding polymicrobial cultures and 
patients with a secondary, concomitant infection. Median time [IQR] to optimal therapy 
from culture collection was decreased from 61.5 [47.8 – 68.1] hours in the conventional 
testing group to 42.5 [21.9 – 56.6] hours in the GeneXpert group (p = 0.003). Time to 
adequate therapy was 4.9 hours in the conventional testing group and 5 hours in the 
GeneXpert group (p=0.658) (Table 2).  
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Median [IQR] length of hospital stay was similar in the conventional testing 
group as compared to the GeneXpert group, 14.5 [9.3 - 48] days vs. 13 [6 – 60.5] days (p 
= 0.541).  
Forty-two patients in the conventional testing group and 22 patients in the 
GeneXpert group had monomicrobial, MSSA-positive blood cultures. In this subset of 
the population, total hours of vancomycin therapy was 48.1 hours in the conventional 
testing group and 25.8 hours in the GeneXpert group (p = 0.009). Total doses of 
vancomycin given also decreased following implementation of GeneXpert (p = 0.014).   
Discussion 
 
In a previous study of blood cultures obtained from pediatric patients, GeneXpert 
was 100% sensitive and specific for MRSA and 100% sensitive and 99.5% specific for 
MSSA.20 In our study, the GeneXpert result was concordant with the identification 
determined by traditional susceptibility testing in 100% of blood cultures.  
Studies assessing clinical outcomes of rapid PCR testing in pediatric patient 
populations are limited. Veesenmeyer and colleagues compared traditional identification 
methods to the combination of peptide nucleic acid and PCR testing for identification and 
susceptibility in pediatric patients at a single children’s hospital. Mean vancomycin 
duration utilization decreased in the total cohort from 53 hours with conventional testing 
to 35 hours in the rapid diagnostic testing group (p=0.01).21 In patients infected with 
MSSA specifically, there was a decrease in the number of patients who received at least 
24 hours of vancomycin therapy from 48% to 15% after implementation of rapid 
diagnostic testing, while mean hours of vancomycin therapy decreased from 30 hours to 9 
hours (p=0.01).21 In our MSSA patients specifically, there was a decrease in the number 
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of patients who received at least 24 hours of vancomycin therapy from 25% to 18.5% in 
our MSSA cohort. Total median hours of vancomycin therapy decreased by about 22 
hours from the conventional testing group to the GeneXpert group, a similar margin of 
decreased hours of vancomycin therapy, despite not having comparable antimicrobial 
stewardship efforts. In our cohort, the total hours of vancomycin utilization is still much 
greater at 25.8 hours as compared to 9 hours. The effects of the GeneXpert may not be 
fully realized at our institution as there is no formalized protocol for response. The 
hospital studied by Veesenmeyer and colleagues has a well-established antimicrobial 
stewardship program which was active prior to and during the study. Unlike in our study, 
the antimicrobial stewardship pharmacist was paged with positive blood culture 
susceptibility results during the hours of 0700-1530, after which results were reviewed 
and recommendations were made.  
In combination with antimicrobial stewardship program interventions in adults 
with SA bacteremia, rapid PCR testing decreases total hospital costs, pharmacy costs and 
time optimal antibiotic therapy.14,19 In a study performed by Bauer and colleagues, the 
infectious disease clinical pharmacist was contacted with the PCR result and effective 
antibiotics were recommended to the team at that time. The mean LOS was 6.2 days 
shorter in the total population in patients with PCR testing (p=0.07) and a mean total 
hospital cost of $21,389 was saved (p=0.02). Carver and colleagues specifically assessed 
the importance of an antimicrobial stewardship intervention after mecA testing by 
comparing outcomes in a group with no formal intervention after mecA gene test results 
to the use of an infectious disease clinical pharmacist to provide clinical 
recommendations at the time of the mecA gene test result. In the group with immediate 
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infectious disease pharmacist intervention, time to optimal antibiotic therapy for patients 
with SA bacteremia was decreased from 64.7 hours to 39.3 hours.  
In the pediatric population, Felsenstein addressed hospital cost in patients 
admitted to the general pediatric unit with SA bacteremia before and after 
implementation of a similar PCR rapid diagnostic test without a formal antimicrobial 
stewardship protocol and noted a non-significant median decrease of approximately 
$13,000.22 Ray and colleagues looked at another PCR testing identification method, again 
with limited formal stewardship involvement and noted fourteen total bed days were 
saved with use of rapid PCR.23 In our patient population, no difference in LOS was 
observed and cost was not assessed. Due to the complex nature of the patient population 
at our hospital, patients often had comorbidities keeping them in the hospital beyond 
resolution of the infection. 
Limitations to this study exist in both methodology and analysis. Due to the 
sample size, we were unable to further analyze variability due to primary medical service, 
primary pharmacist, or primary physician. At our institution, patients can be medically 
complex and it was challenging to account for all of the potential factors which could 
impact a patient’s antibiotic therapy. We tried to combat this by assessing whether 
patients had monomicrobial, polymicrobial, concomitant, or secondary infection. In 
doing so, we were able to exclusively analyze patients with a primary SA infection to 
capture de-escalation. Additionally, while we accounted for altered optimal therapy in 
febrile neutropenia patients, there was not a large enough sample of this patient 
population to analyze these patients individually. Information was not collected regarding 
the interventions made on weekdays as compared to weekends to assess the impact of 
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having rounding clinical pharmacists Monday through Friday. It is unknown how the 
time immediately following implementation, which was included in the post-intervention 
period, could have impacted the results. It is possible that as time went on and prescribers 
became more comfortable with the test, vancomycin exposure and time to therapy 
alteration decreased. This was not evaluated in the current study.  Safety outcomes were 
not measured in this study, including potential adverse effects as a result of receiving 
vancomycin therapy.  
Conclusions 
In our pediatric population, the utilization of PCR testing to identify the presence 
of the mecA gene in SA blood cultures was associated with a decreased time to optimal 
therapy from culture collection. In patients with monomicrobial MSSA blood cultures, a 
significant difference in the total hours of vancomycin therapy was appreciated. Hospital 
length of stay in this cohort was not significantly impacted. It is unknown whether a 
formalized antimicrobial stewardship protocol for response would have a greater impact 
on these outcomes. Further studies are warranted to determine the impact of this rapid 
diagnostic testing method with varied antimicrobial stewardship responses in a variety of 
pediatric populations.  
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Table 1: Baseline characteristics 
 
 Conventional  
(n = 61) 
GeneXpert  
(n = 40) 
p-value 
Malea 60.7 (37) 57.5 (23) 0.752 
Age, yearsb 4.8 [0.4 – 10.8] 7.4 [0.3 – 14.1] 0.194 
Weight, kgb 16.7 [5.3 – 37.6] 20.6 [5.3 – 46.4] 0.236 
adata reported as % (n) 
bdata reported as median [IQR] 
 
Table 2: Time to therapy 
 
 Conventional  
(n = 50) 
GeneXpert (n = 
32) 
p=value 
Time to optimal 
therapy from 
culture 
collection, 
hoursa 
61.5 
[47.8 – 68.1] 
42.5 
[21.9 – 56.6] 
0.003 
Time to optimal 
therapy from 
culture result, 
hoursa 
22.8  
[-5.7 – 26.8] 
2  
[-22.6 – 25.7] 
0.225 
Time to 
adequate 
therapy from 
culture 
collection, 
hoursa 
4.9  
[2.2 – 15.3] 
5  
[0.9 – 16.4] 
0.658 
adata reported as median [IQR] 
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Figure 1 
 
 
Patients with a positive SA blood culture from 
February 1, 2014 through March 31, 2015 or 
February 1, 2016 through March 31, 2017
(n = 110)
mecA identified by conventional 
methods only
(n = 61)
mecA identified via RDT
(n = 40)
Excluded due to death, non-standard 
laboratory procedures, missing EMR data, 
or blood culture contaminate
(n = 9)
